These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25964862)

  • 1. Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.
    Wouters M; Dijkgraaf EM; Kuijjer ML; Jordanova ES; Hollema H; Welters M; van der Hoeven J; Daemen T; Kroep JR; Nijman HW; van der Burg SH
    Oncoimmunology; 2014 Dec; 3(12):e962397. PubMed ID: 25964862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.
    de Vos van Steenwijk PJ; Ramwadhdoebe TH; Goedemans R; Doorduijn EM; van Ham JJ; Gorter A; van Hall T; Kuijjer ML; van Poelgeest MI; van der Burg SH; Jordanova ES
    Int J Cancer; 2013 Dec; 133(12):2884-94. PubMed ID: 23740735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
    Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Wouters MC; Kenter GG; van Erkel AR; van Poelgeest MI; Nijman HW; van der Hoeven JJ; Welters MJ; van der Burg SH; Kroep JR
    Ann Oncol; 2015 Oct; 26(10):2141-9. PubMed ID: 26216383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
    Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
    Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells.
    Horikawa N; Abiko K; Matsumura N; Hamanishi J; Baba T; Yamaguchi K; Yoshioka Y; Koshiyama M; Konishi I
    Clin Cancer Res; 2017 Jan; 23(2):587-599. PubMed ID: 27401249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.
    Nonaka K; Saio M; Suwa T; Frey AB; Umemura N; Imai H; Ouyang GF; Osada S; Balazs M; Adany R; Kawaguchi Y; Yoshida K; Takami T
    J Leukoc Biol; 2008 Sep; 84(3):679-88. PubMed ID: 18566103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic value of tumor infiltration immune cells in pancreatic cancer].
    Zhao KL; Liu J; Jiang WN; Hao JH
    Zhonghua Wai Ke Za Zhi; 2018 Jun; 56(6):464-470. PubMed ID: 29886672
    [No Abstract]   [Full Text] [Related]  

  • 8. The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.
    Ujiie H; Kadota K; Nitadori JI; Aerts JG; Woo KM; Sima CS; Travis WD; Jones DR; Krug LM; Adusumilli PS
    Oncoimmunology; 2015 Jun; 4(6):e1009285. PubMed ID: 26155428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Merkel cell carcinomas infiltrated with CD33
    Kervarrec T; Gaboriaud P; Berthon P; Zaragoza J; Schrama D; Houben R; Le Corre Y; Hainaut-Wierzbicka E; Aubin F; Bens G; Domenech J; Guyétant S; Touzé A; Samimi M
    J Am Acad Dermatol; 2018 May; 78(5):973-982.e8. PubMed ID: 29273486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Cells Interleukin-22 Expression Associates with Elevated Tumor-Associated Macrophages Infiltrating and Poor Prognosis in Patients with Breast Cancer.
    Zhao J; Liu H; Zhang X; Zhang W; Liu L; Yu Y; Ren S; Yang Q; Liu B; Li J; Li X; Liu Y; Zhao L
    Cancer Biother Radiopharm; 2021 Mar; 36(2):160-166. PubMed ID: 33090014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
    Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
    Front Immunol; 2019; 10():1273. PubMed ID: 31214202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPECT imaging of interleukin-6 receptor in ovarian tumor xenografts with a novel radiotracer of 99mTc-HYNIC-Aca-LSLITRL.
    Li F; Zhang Z; Cheng T; Wei R; Dai Y; Lv M; Luo D; Zhu X; Ma D; Xi L; Dong Q; Ma X
    Amino Acids; 2016 Jan; 48(1):91-101. PubMed ID: 26255282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
    Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
    Front Immunol; 2019; 10():691. PubMed ID: 31001284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells.
    Lee BR; Kwon BE; Hong EH; Shim A; Song JH; Kim HM; Chang SY; Kim YJ; Kweon MN; Youn JI; Ko HJ
    Cancer Lett; 2016 Oct; 381(1):156-64. PubMed ID: 27431309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors
    Koneru M; Purdon TJ; Spriggs D; Koneru S; Brentjens RJ
    Oncoimmunology; 2015 Mar; 4(3):e994446. PubMed ID: 25949921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
    Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6/IL-6R pathway is a therapeutic target in chemoresistant ovarian cancer.
    Yousefi H; Momeny M; Ghaffari SH; Parsanejad N; Poursheikhani A; Javadikooshesh S; Zarrinrad G; Esmaeili F; Alishahi Z; Sabourinejad Z; Sankanian G; Shamsaiegahkani S; Bashash D; Shahsavani N; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A
    Tumori; 2019 Feb; 105(1):84-91. PubMed ID: 30021477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.
    Santegoets SJAM; de Groot AF; Dijkgraaf EM; Simões AMC; van der Noord VE; van Ham JJ; Welters MJP; Kroep JR; van der Burg SH
    Oncoimmunology; 2018; 7(8):e1465166. PubMed ID: 30221063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.